Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/56244
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMarc M. Solomonen_US
dc.contributor.authorMauro Schechteren_US
dc.contributor.authorAlbert Y. Liuen_US
dc.contributor.authorVanessa M. McManhanen_US
dc.contributor.authorJuan V. Guaniraen_US
dc.contributor.authorRobert J. Hanceen_US
dc.contributor.authorSuwat Chariyalertsaken_US
dc.contributor.authorKenneth H. Mayeren_US
dc.contributor.authorRobert M. Granten_US
dc.contributor.authorLinda Gail Bekkeren_US
dc.contributor.authorSusan Buchbinderen_US
dc.contributor.authorMartin Casapiaen_US
dc.contributor.authorEsper Kallasen_US
dc.contributor.authorJavier Lamaen_US
dc.contributor.authorOrlando Montoyaen_US
dc.contributor.authorValdiléa Velosoen_US
dc.date.accessioned2018-09-05T03:11:22Z-
dc.date.available2018-09-05T03:11:22Z-
dc.date.issued2016-01-01en_US
dc.identifier.issn10779450en_US
dc.identifier.issn15254135en_US
dc.identifier.other2-s2.0-84959166158en_US
dc.identifier.other10.1097/QAI.0000000000000857en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84959166158&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/56244-
dc.description.abstractCopyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. Background: Pre-exposure prophylaxis (PrEP) with daily oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) prevents HIV infection. The safety and feasibility of HIV PrEP in the setting of hepatitis B virus (HBV) infection were evaluated. Methods: The Iniciativa Profilaxis Pre-Exposición study randomized 2499 HIV-negative men and transgender women who have sex with men to once-daily oral FTC/TDF versus placebo. Hepatitis serologies and transaminases were obtained at screening and at the time PrEP was discontinued. HBV DNA was assessed by polymerase chain reaction, and drug resistance was assessed by population sequencing. Vaccination was offered to individuals susceptible to HBV infection. Results: Of the 2499 participants, 12 (0.5%; including 6 randomized to FTC/TDF) had chronic HBV infection. After stopping FTC/ TDF, 5 of the 6 participants in the active arm had liver function tests performed at follow-up. Liver function tests remained within normal limits at post-stop visits except for a grade 1 elevation in 1 participant at post-stop week 12 (alanine aminotransferase = 90, aspartate aminotransferase = 61). There was no evidence of hepatic flares. Polymerase chain reaction of stored samples showed that 2 participants in the active arm had evidence of acute HBV infection at enrollment. Both had evidence of grade 4 transaminase elevations with subsequent resolution. Overall, there was no evidence of TDF or FTC resistance among tested genotypes. Of 1633 eligible for vaccination, 1587 (97.2%) received at least 1 vaccine; 1383 (84.7%) completed the series. Conclusions: PrEP can be safely provided to individuals with HBV infection if there is no evidence of cirrhosis or substantial transaminase elevation. HBV vaccination rates at screening were low globally, despite recommendations for its use, yet uptake and efficacy were high when offered.en_US
dc.subjectMedicineen_US
dc.titleThe safety of tenofovir-emtricitabine for HIV pre-exposure prophylaxis (PrEP) in individuals with active hepatitis Ben_US
dc.typeJournalen_US
article.title.sourcetitleJournal of Acquired Immune Deficiency Syndromesen_US
article.volume71en_US
article.stream.affiliationsThe J. David Gladstone Institutesen_US
article.stream.affiliationsUniversity of California, San Franciscoen_US
article.stream.affiliationsHospital Escola Sao Francisco de Assisen_US
article.stream.affiliationsSan Francisco Department of Public Healthen_US
article.stream.affiliationsInvestigaciones Medicas en Saluden_US
article.stream.affiliationsChiang Mai Universityen_US
article.stream.affiliationsBeth Israel Deaconess Medical Centeren_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.